At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PolyEnv1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 22, 2003·Updated Jun 8, 2011
In Brief
A Phase 1 clinical trial evaluating PolyEnv1 for HIV Infections. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore the vaccine cannot itself cause HIV or AIDS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 1997
First PostedJan 2003
Primary CompletionJul 2006
Study CompletionJun 2009
TodayJul 2026
First PostedJan 22, 2003
Enrollment StartOct 1, 1997
Primary CompletionJul 1, 2006
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 23.4 years ago
Interventions
PolyEnv1biological
Recombinant vaccinia virus vaccine